



## **Crescendo Biologics Recognised at OBN Annual Awards Dinner**

### **Runner up in 'Best Emerging Biotech Fundraiser' Category**

Cambridge, UK. 3<sup>rd</sup> October 2014 – Crescendo Biologics Limited (Crescendo) was last night named runner up in the *Best Emerging Biotech Fundraiser* category at the OBN Annual Awards Dinner.

The Company was recognised for its £19.5m Series A financing led by Imperial Innovations and including new investors Astellas Venture Management (AVM) and EMBL Ventures. Founding seed investor Sofinnova Partners also contributed significantly to the round.

The winner in the category was Circassia which raised £200m in its IPO on the London Stock Exchange, listing at the top of its range and valuing the company at £581m. Circassia's cat allergy vaccine is in Phase 3 trials.

The OBN Annual Awards ceremony was held at the Ashmolean Museum, Oxford.

Jon Rees, OBN's CEO, commented: "The quality of nominees continues to rise year on year. Compiling a shortlist and picking winners gets harder. We have the opportunity to applaud the cream of successful public-private collaborations turning ideas into clinical practice, investors who take the risks and support promising projects, and the pharmaceutical companies that use their commercial skills to bring products to market."

#### **Contacts**

Mike Romanos  
Crescendo Biologics  
Tel: +44 (0) 1223 497140  
Email: [mromanos@crescendobiologics.com](mailto:mromanos@crescendobiologics.com)

Chris Gardner  
Citigate Dewe Rogerson  
Tel: +44 (0)207 638 9571  
Email: [chris.gardner@citigatedr.co.uk](mailto:chris.gardner@citigatedr.co.uk)

#### **About Crescendo Biologics Ltd**

Crescendo Biologics, based in Cambridge, UK, is focused on the discovery and development of Humabodies™, best-in-class human V<sub>H</sub> antibody fragment therapeutics, using its novel transgenic platform. Crescendo is enabling the major V<sub>H</sub> product formats (multivalent, half-life-extended and topical) for its own pipeline, focused in inflammation and oncology, and to make it the partner of choice for human V<sub>H</sub> fragment therapeutics.

[www.crescendobiologics.com](http://www.crescendobiologics.com)

#### **About OBN**

OBN is the Membership organisation supporting and bringing together the UK's emerging life sciences companies, corporate partners and investors. Our 350-plus Member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland. Information about OBN's tailored networking and partnering events, purchasing consortium, advice, consultancy services and advocacy activities is available on OBN's website [www.obn.org.uk](http://www.obn.org.uk).